article · Egyptian Rheumatology and Rehabilitation
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that presents as a symmetrical polyarthritis characterized by joint pain, swelling, and stiffness. This study aimed to evaluate the expression of microRNA-24-3p (miRNA-24-3p), in the plasma of RA patients and compare it with that of healthy controls with the goal of establishing a specific expression profile for early diagnosis and improved patient care. This case-control study was carried out on 100 RA patients attending Rehabilitation and Physical Medicine department and 50 age and sex-matched control individuals. Disease severity score (DAS-28) was used to assess the disease’s level. Real-time polymerase chain reaction (qPCR) was used for detection of plasma level of miRNA-24-3p and other lab tests including blood picture, c-reactive protein (CRP), erythrocytes sedimentation rate (ESR) and anti-cyclic citrullinated peptide (anti-CCP) were also performed. The miRNA-24-3p expression was statistically significant higher among RA cases than controls (p < 0.001) and was positively associated with higher ESR, white blood cells (WBCs) and along with the number of tendered/swallow joints (p < 0.05). Higher CRP, ESR, Anti-CCP, and miRNA-24-3p expression were found to be significant predictors of DAS28 scores in univariable analysis. Higher CRP and miRNA-24-3p expression exhibit substantial impact in multivariate analysis, indicating a strong statistical significance in their association with higher DAS28 grades. The elevated expression of miR-24-3p suggests its probable contribution to both the onset of RA and the activity measured by DAS28 score. Consequently, assessing its expression levels may serve as a valuable tool for the diagnosis and management of RA.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1186/s43166-026-00391-3
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.